MED12 is a member of the large Mediator complex that controls cell growth, development, and differentiation. Mutations in MED12 disrupt neuronal gene expression and lead to at least three distinct X-linked intellectual disability syndromes (FG, Lujan-Fryns, and Ohdo). Here, we describe six families with missense variants in MED12 (p.(Arg815Gln), p.(Val954Gly), p.(Glu1091Lys), p.
(Arg1295Cys), p.(Pro1371Ser), and p.(Arg1148His), the latter being first reported in affected females) associated with a continuum of symptoms rather than distinct syndromes. The variants expanded the genetic architecture and phenotypic spectrum of MED12-related disorders. New clinical symptoms included brachycephaly, anteverted nares, bulbous nasal tip, prognathism, deep set eyes, and single palmar crease. We showed that MED12 variants, initially implicated in X-linked recessive disorders in males, may predict a potential risk for phenotypic expression in females, with no correlation of the X chromosome inactivation pattern in blood cells. Molecular modeling (Yasara Structure) performed to model the functional effects of the variants strongly supported the pathogenic character of the variants examined. We showed that molecular modeling is a useful method for in silico testing of the potential functional effects of MED12 variants and thus can be a valuable addition to the interpretation of the clinical and genetic findings.
| INTRODUCTION
The Mediator is a large multiprotein complex that regulates gene expression in all eukaryotes and interacts with RNA polymerase II. The role of the complex involves transcriptional elongation and termination, mRNA processing, noncoding RNA activation, super enhancer formation, and epigenetic regulation. Thus, the Mediator was called an "integrative hub" for transcriptional processes and emerged as a master coordinator of cell growth and homeostasis, development, and differentiation. 1 The Mediator complex (MED) con- 
| MATERIALS AND METHODS
Six ID families with MED12 variants (NM_005120) were included in the study (Figure 1 ). Patients' phenotypes are described in File S1, 
| RESULTS
We report on 13 affected males and two affected females from six families with variants in the MED12 gene ( Figure 1 ). Clinical symptoms of the affected males and females along with a comparison with symptoms described in published MED12-related syndromes are presented in Table 1 . All probands had ID and developmental delay, and most of them had macrocephaly, long narrow face, prominent forehead, small ears, dental abnormalities, prognathism, and hypertelorism. 
| DISCUSSION
The phenotypic spectrum of MED12-related disorders is still being expanded as new families with MED12 variants are being identified due to the improvement of new sequencing technologies. Moreover, it was postulated that succeeding syndromes should be defined to extend the list of the three allelic syndromes associated with MED12 mutations. However, as shown by the clinical data of our probands (Table 1) , it seems that they do not manifest strict syndromes (FGS1, Lujan-Fryns, or Ohdo), but they rather present, similar to recently published data, 5 a continuum of symptoms. Thus, it is more appropriate to indicate only a 'MED12-related disorder' than to attribute a definite syndrome for a majority of the subjects.
To date, over 20 MED12 genetic variants have been reported, which are evenly distributed with no apparent hot spots in specific exons ( Figure 1 ). All but one were missense variants causing FGS1, Lujan-Fryns, Ohdo syndrome, or nonsyndromic ID with different degrees of cognitive impairment. Many benign variants (456 in ClinVar)
were also described as well as somatic variants implicated in cancer but not associated with germline mutations. The MED12 variants examined in the current study were defined as pathogenic by molecular modeling, the approach that is not only based on bioinformatic prediction, but also uses experimentally gained protein crystal structures. The results suggested a pathogenic effect of all four MED12 variants tested: p. 
